TD Cowen analyst Tara Bancroft downgraded Day One Biopharmaceuticals (DAWN) to Hold from Buy with a price target of $21.50, down from $24. The 68% premium over the March 5 closing price represents “a justifiable acquisition value” that prices in fair value for Ojemda, DAY301, and Emi-Le, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
- Day One Biopharmaceuticals downgraded to Hold from Buy at Needham
- Day One Biopharmaceuticals downgraded to Neutral from Outperform at Wedbush
- Day One Biopharmaceuticals downgraded to Hold from Buy at JonesResearch
- Servier to Acquire Day One Biopharmaceuticals in Merger